Goliath-B (01672) rallied by about 9 per cent in early trading, Zhitong Financial APP learned. The latest news shows that the company is newly selected into the MSCI China Mini Index. At the same time, the company recently said that its COVID-19 drug candidate 3CL protease inhibitor ASC11 is expected to submit to IND in the second half of the year and complete the phase I trial by the end of the year. As of press time, Golly Pharmaceuticals rose 8.77% to HK $3.97, with a turnover of HK $11 million.

Last month, Golly Pharmaceutical-B (01672) announced the antiviral cell trial of 3CL protease inhibitor ASC11, a candidate drug for oral small molecule COVID-19, which initially outperformed similar drugs in terms of data. The company expects to submit an application for a clinical trial in the second half of 2022 and complete a phase I clinical trial in healthy subjects by the end of 2022.

According to Guojin Securities, the company's other oral drug COVID-19 ASC10 is Goliath independent research and development of RdRp target COVID-19 oral drug. Compared with Molnupiravir, the permeability of ASC10 in Caco-2 cells was 3.2 times higher than that of Molnupiravir. Golly plans to submit clinical trial applications to China, the United States and other countries in the first half of 2022.